ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2271

Correlation of Silent Brain Infarction with the Metabolic Abnormality of CKD Stage 3-5 (Nondialytic) Patients

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Author

  • Hasan, Md Naheed, Dhaka Medical College and Hospital, Dhaka, Bangladesh
Background

Silent brain infarction (SBI) is a hidden comorbidity, mostly unrecognized in CKD patients which increases the risk of symptomatic stroke, dementia and overt neurological mortality. The relationship between SBI and chronic kidney disease (CKD) is unknown. It is supposed that SBI will predict the progression of diseases processes in CKD patients.

Methods

This is a cross-sectional study. A total of 115 subjects were enrolled in this study. 85 patients of CKD stage3-5 (non dialytic) who have no neurological symptoms suggesting stroke were considered as group I and Group-II were 30 healthy controlI. Glomerular filtration rate (GFR) was estimated using MDRD-equation. All study subjects underwent MRI.

Results

The proportion of Silent Brain Infarction is 52.9% in CKD patients. SBI was found in 45(52.9%) patients in group I and 4(13.3%) in group II which was significant (p<0.05). The proportion of SBI was also increased in higher CKD stages. (stage-3:8.9%; stage-4:35.6%; stage-5ND:55.6%). In a multivariate logistic regression analysis CKD had independent relationship with SBI along with serum phosphate and parathyroid hormone level (CKD had Odds ratio (OR)=1.847 (95.0% C.I 0.064 to 53.319), serum PO4 had OR=0.958 (95.0% C.I. 0.885 to 1.038) and serum PTH had OR=0.996 (95.0% C.I. 0.993 to 1.000). Spearman rank correlation coefficient test showed positive correlation between SBI and serum PO4 level (r=0.416; p=0.001) and serum PTH level (r= 0.405; p=0.001) separately.

Conclusion

The proportion of SBI in CKD stage 3-5(non dialytic) patients is high which is 52.9% and serum PO4 and serum PTH level have positive correlation with the development of SBI in CKD stage 3-5(non dialytic) patients.

Funding

  • Clinical Revenue Support